Therapeutic Goods Administration announces deferral of codeine decision
The Therapeutic Goods Administration (TGA) has deferred a final decision on the proposed rescheduling of over the counter codeine-containing medicines to prescription-only.
The interim decision to support the re-scheduling of combination analgesics and cold and flu remedies containing codeine from Schedules 2 and 3 to Schedule 4 was made last month in response to a recommendation by the Advisory Committee on Medicines Scheduling (ACMS).
![](/sites/default/files/styles/limit_height/public/documents/Medical_Student.jpg?itok=jiFQ7PDw)
However, during the most recent consultation period, 113 of the 127 submissions received did not support the proposal. The TGA medicines scheduling delegate said the deferral of a decision will allow the large number of submissions to be thoroughly considered.
The AMA continues to support the independent, evidence-based process of the ACMS in developing its recommendations.